Personalized immunotherapy for early-stage unfavorable Hodgkin lymphoma
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial studies a customized immune-based treatment approach for people with early-stage “unfavorable” classical Hodgkin lymphoma who have not had prior treatment. It may help by targeting your lymphoma using an individualized plan based on your case.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have classical Hodgkin lymphoma and it is your first diagnosis with no prior treatment
- Your disease is early-stage but considered “unfavorable,” such as a large chest (mediastinal) mass or other listed risk factors
- You have certain risk features, which may include one or more of the following: large mediastinal mass, spread outside lymph nodes, high inflammation marker (ESR), or involvement of 3+ lymph node areas
- Your age fits the study: 18–60 for the main group, or 61+ may qualify if you are eligible for AVD treatment based on health scoring (CIRS-G) and the doctor’s judgment
- You do NOT have nodular lymphocyte-predominant Hodgkin lymphoma, grey-zone lymphoma, or lymphoma involving the brain or spinal cord
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines an immunotherapy drug (a type of treatment that helps your immune system fight cancer) with radiation therapy for people with early-stage classic Hodgkin lymphoma. The goal is to see if this combination can treat the cancer effectively while possibly reducing side effects.
This trial tests a combination of the immunotherapy drug sintilimab with chemotherapy (AVD) for children and teens with newly diagnosed low- or intermediate-risk Hodgkin lymphoma. The goal is to see if adding sintilimab can improve outcomes while reducing side effects.
This trial is looking at new ways to predict how Hodgkin lymphoma will respond to treatment. It collects blood and tumor samples at key times to see if these can help doctors make better treatment decisions in the future.
This trial tests a drug called pembrolizumab as the first treatment for advanced-stage classical Hodgkin lymphoma. It may help shrink tumors and keep the disease from getting worse.
This Phase 2 trial tests tislelizumab (an immune therapy) in people with newly diagnosed classical Hodgkin lymphoma who cannot safely get standard chemotherapy. It aims to see how well the treatment works and whether it is safe for older adults and others with health limits.
This trial tests a drug called tislelizumab (an immunotherapy that helps your immune system fight cancer) added to standard chemotherapy for older adults with newly diagnosed Hodgkin lymphoma. The goal is to see if adding this drug improves outcomes without too many side effects.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.